Scope and Claim Analysis for US Patent 10,842,770: Non-Aqueous Docetaxel Liquid Pro-Emulsion (PEG, Polysorbate, Oil, Organic Acids; No Ethanol) and Administering Methods
US 10,842,770 is a formulation-and-use patent centered on a non-aqueous docetaxel “liquid pro-emulsion” that converts to an intravenous docetaxel emulsion upon mixing with an aqueous medium. The claims are tightly constrained by (i) compositional ranges (PEG 35-55% w/w, polysorbate 30-70% w/w, oil 0.5-5% w/w, organic acid 0.3-3% w/w, docetaxel 0.1-5% w/w), (ii) specific component selections (organic acid limited to acetic, lactic, or citric; oil limited to defined triglyceride sources and MCT; polysorbate assumed limited by dependent claims), (iii) a hard exclusion of ethanol, and (iv) a quantitative relationship between docetaxel and oil (their amounts differ by no more than 50% w/w; a tighter 10% w/w appears in dependent form). Independent claim 1 also addresses particle formation quality through dependent claims (3-70 nm) and specifies suitable PEG molecular weight (≤1000).
What exactly is claimed in US 10,842,770?
Executive claim coverage (what you’d read on a claim chart)
Independent claim 1 protects a specific class of non-aqueous docetaxel pro-emulsion compositions with the following mandatory elements:
- Drug form: anhydrous docetaxel or a hydrate thereof, at 0.1 to 5% w/w.
- Organic acid: 0.3 to 3% w/w selected from:
- acetic acid
- lactic acid
- citric acid
- Oil component: 0.5 to 5% w/w selected from:
- soybean oil
- olive oil
- sesame oil
- corn oil
- medium chain triglyceride (MCT)
- combinations
- Polysorbate component: 30 to 70% w/w (independent claim does not name which polysorbate; dependent claim 5 locks to polysorbate 80).
- Non-aqueous solvent component: polyethylene glycols 35 to 55% w/w.
- Ethanol is excluded: “wherein the formulation does not include ethanol.”
- Quantitative relationship: “wherein the amount of the docetaxel and the amount of the oil component differ by 50% w/w or less.”
- Pro-emulsion concept: “liquid pro-emulsion” intended to form a docetaxel emulsion upon mixing with aqueous medium is made operational in claim 6 and claim 7, and partially in claim 13.
Independent claim 6 protects a two-step administration method:
- (a) combine the claim 1 formulation with an aqueous medium to produce a docetaxel emulsion
- (b) intravenously administer the emulsion
Independent claim 7 protects a kit:
- claim 1 pro-emulsion formulation plus an aqueous medium suitable for IV injection.
Dependent claims tighten composition or performance:
- Claim 2: docetaxel trihydrate specifically.
- Claim 3: soybean oil specifically.
- Claim 4: docetaxel and oil differ by 10% w/w or less (tightens the independent 50% rule).
- Claim 5: polysorbate 80 specifically.
- Claim 8: PEG 300 specifically (within the PEG family).
- Claim 9: oil restricted to soybean oil or MCT.
- Claim 10: the most specific combo: soybean oil + polysorbate 80 + PEG 300.
- Claim 11: upon addition to aqueous medium, particle size 3 to 70 nm.
- Claim 12: PEG molecular weight 1000 or less.
- Claim 13: suitability for preparation of an intravenously injectable composition.
How narrow is the claim 1 scope for competing docetaxel products?
Claim 1 is narrow in several independent ways, meaning many “adjacent” docetaxel reformulations fall outside.
1) Ethanol exclusion is a hard boundary
Claim 1 explicitly excludes ethanol. Any docetaxel pro-emulsion or solvent system relying on ethanol as a solubilizer is outside claim 1 literal scope.
2) PEG and polysorbate are constrained by ranges that must both be met
Claim 1 mandates:
- PEG 35–55% w/w, and
- polysorbate 30–70% w/w.
This creates a two-dimensional numeric requirement. A formulation that shifts solvent burden (e.g., more PEG, less polysorbate) may fall outside.
3) Organic acid is limited to three specific acids, at specified w/w
Only acetic, lactic, and citric acids qualify, and only within 0.3–3% w/w. Substituting other acids (for example, tartaric, phosphoric, etc.) or shifting acid level outside range is outside literal scope.
4) Oil selection is limited to specified oils/MCT
Claim 1 oil must be one of the specified oils or MCT, and within 0.5–5% w/w.
5) Quantitative relationship: docetaxel vs oil is a structural limiter
The claim requires that the amounts of docetaxel and oil differ by ≤50% w/w. This is not a typical “ratio” clause stated as a ratio, but a numeric difference limit.
Practical interpretation for design-around: the formulation must keep docetaxel mass fraction and oil mass fraction close enough that their difference does not exceed the specified threshold. A competitor could try to move oil and docetaxel far enough apart (while still inside their separate ranges) to break the relationship without violating the ranges.
6) The dependent claim 4 is an even tighter version
Claim 4 limits the difference to ≤10% w/w. If a product targets a composition not meeting the tighter difference but meeting the broader claim 1 difference, it might still avoid dependent coverage while remaining exposed to claim 1.
What are the key dependent claim “claim ladders” and what do they add?
Dependent claim ladder (from generic class to specific product profile)
- Claim 2 locks docetaxel to trihydrate.
- Claim 3 locks oil to soybean oil.
- Claim 5 locks polysorbate to polysorbate 80.
- Claim 8 locks PEG to PEG 300.
- Claim 10 combines the above: soybean oil + polysorbate 80 + PEG 300.
- Claim 11 locks performance: 3–70 nm particle size after aqueous mixing.
- Claim 12 locks PEG molecular weight: ≤1000.
- Claim 4 and the independent difference condition (50%) are tighteners.
“Most vulnerable” formulation profile
A formulation matching:
- docetaxel 0.1–5% w/w,
- soybean oil 0.5–5% w/w,
- PEG 300 35–55% w/w,
- polysorbate 80 30–70% w/w,
- no ethanol,
- with docetaxel and oil differ by ≤10% w/w (if you meet claim 4),
- and produces 3–70 nm particles on aqueous mixing (if you meet claim 11)
would stack coverage across claims 1, 3, 4, 5, 8, 10, and 11 simultaneously.
“Easiest” ways to step outside dependent claims without leaving claim 1 entirely
- Switch docetaxel from trihydrate to another hydrate or anhydrous form to avoid claim 2 while still meeting claim 1.
- Use polysorbate other than 80 to avoid claim 5 while remaining in the polysorbate range of claim 1.
- Use PEG other than PEG 300 to avoid claim 8.
- Use oils other than soybean oil (olive, sesame, corn, MCT) to avoid claim 3.
- Engineer particle size outside 3–70 nm after aqueous mixing to avoid claim 11, while still maintaining the compositions of claim 1.
- Use PEG molecular weights >1000 to avoid claim 12, while still meeting claim 1’s “polyethylene glycols 35–55%” (note: claim 12 is dependent, so claim 1 could still be met unless molecular weight impacts formulation.
What does claim 6 add versus the formulation claims?
Claim 6 is a procedural-use claim tied directly to claim 1:
- combine claim 1 pro-emulsion with an aqueous medium to form a docetaxel emulsion
- intravenously administer.
This matters because a party could manufacture a pro-emulsion composition outside claim 1 scope but still perform an administration workflow that would only be captured if the administered mixture falls within claim 1’s composition. Claim 6 does not broaden beyond claim 1’s formulation definition; it extends protection to administration practice for qualifying compositions.
What does claim 7 (kit) practically protect?
Claim 7 protects a kit containing:
- (a) the claim 1 pro-emulsion formulation
- (b) an aqueous medium suitable for IV injection.
This closes a common gap where a manufacturer sells the concentrate but leaves dilution to a separate provider. A kit sale aligns with how hospitals or commercial providers stage reconstitution/dilution.
How does the particle size claim affect infringement analysis?
Claim 11 adds a performance attribute: particle size 3 to 70 nm upon addition to aqueous medium.
For infringement posture:
- If the product forms particles in that range after mixing, claim 11 is likely implicated for the qualifying composition base.
- If the particle size distribution shifts outside that range through formulation or mixing conditions, claim 11 may be avoided even if the composition meets claim 1.
Claim 11 also interacts with manufacturing and testing controls. Particle size is often method-dependent (DLS vs laser diffraction; sampling points). The claim language as given ties to the “upon the addition to an aqueous medium” particle size interval.
What is the likely patent landscape shape around this claim set?
Based only on the claim text provided, the landscape is centered on:
- docetaxel solvent/emulsion stabilization systems,
- ethanol-free docetaxel formulations,
- non-aqueous pro-emulsion concentrates that convert to IV emulsions on mixing,
- PEG/polysorbate/oil/organic-acid stabilization,
- and downstream quality targets (particle size).
The most likely competitive risk is from other docetaxel reformulations that:
- also rely on polysorbate and PEG,
- avoid ethanol,
- use triglyceride-type oils,
- and use organic acids for pH/compatibility or interface control.
The most likely “escape” from claim 1 is to deviate from at least one of the hard elements:
- include ethanol,
- substitute non-listed organic acids or adjust levels outside 0.3–3%,
- substitute oil types outside the listed set or levels outside 0.5–5%,
- shift PEG or polysorbate outside their ranges,
- or break the docetaxel-oil amount difference constraint.
Claim-by-claim scope matrix (what each claim captures)
| Claim |
Coverage type |
Mandatory limitations (from provided claims) |
Practical capture target |
| 1 |
Formulation |
Docetaxel (anhydrous or hydrate) 0.1–5% w/w; organic acid 0.3–3% w/w (acetic/lactic/citric); oil 0.5–5% w/w (soybean/olive/sesame/corn/MCT/combinations); polysorbate 30–70% w/w; PEG 35–55% w/w; no ethanol; docetaxel vs oil difference ≤50% w/w |
Core ethanol-free docetaxel pro-emulsion concentrate |
| 2 |
Formulation (variant) |
Docetaxel is docetaxel trihydrate |
Trihydrate version |
| 3 |
Formulation (variant) |
Oil is soybean oil |
Soybean-oil subset |
| 4 |
Formulation (tight numeric) |
Docetaxel and oil differ by ≤10% w/w |
Narrow concentration balance subset |
| 5 |
Formulation (variant) |
Polysorbate is polysorbate 80 |
Polysorbate-80 subset |
| 6 |
Method |
Combine claim 1 formulation with aqueous medium to produce docetaxel emulsion; IV administer |
Use of qualifying concentrate in IV workflow |
| 7 |
Kit |
Claim 1 formulation + aqueous medium suitable for IV injection |
Commercial kit bundling |
| 8 |
Formulation (variant) |
Non-aqueous solvent comprises PEG 300 |
PEG-300 subset |
| 9 |
Formulation (variant) |
Oil is soybean oil or MCT |
Soybean/MCT-only subset |
| 10 |
Formulation (combo) |
Oil soybean; polysorbate 80; PEG 300 |
“Product fingerprint” combination |
| 11 |
Formulation/performance |
Particle size after aqueous addition 3–70 nm |
Particle-size constrained embodiment |
| 12 |
Formulation (variant) |
PEG avg molecular weight ≤1000 |
Low-MW PEG subset |
| 13 |
Formulation utility |
Suitable for preparation of an intravenously injectable composition |
Supports practical IV utility for qualifying formulations |
Key takeaways
- US 10,842,770 claim 1 protects an ethanol-free, PEG/polysorbate/oil/organic-acid non-aqueous docetaxel pro-emulsion with strict w/w ranges and a docetaxel-oil amount difference constraint (≤50% w/w).
- Dependent claims narrow to docetaxel trihydrate, soybean oil, polysorbate 80, PEG 300, PEG MW ≤1000, and a particle size window (3–70 nm) after aqueous mixing.
- Method claim 6 and kit claim 7 do not broaden composition; they add protection to administration and commercialization when the underlying concentrate meets claim 1.
- The most direct design-around routes are to violate at least one hard boundary: the no-ethanol requirement, the listed organic acid set and its range, the oil set and its range, PEG/polysorbate ranges, or the docetaxel-vs-oil amount difference constraint.
FAQs
1) Would an ethanol-containing docetaxel emulsion concentrate infringe claim 1?
Not under claim 1 as written, because it expressly requires “the formulation does not include ethanol.”
2) Does claim 6 cover any docetaxel emulsion formed from aqueous dilution, even if the concentrate is different?
No. Claim 6 is limited to combining the claim 1 pro-emulsion formulation with an aqueous medium to produce the emulsion.
3) If a product uses polysorbate other than 80, is it automatically outside the patent?
It may avoid claim 5 (polysorbate 80), but it could still fall within claim 1 if the product meets claim 1’s polysorbate 30–70% w/w and other required limitations.
4) Can a formulation meet claim 1 but avoid claim 11 by changing particle size?
Yes. Claim 11 is dependent and adds a specific particle-size range after aqueous addition; moving particle size outside 3–70 nm would avoid that dependent limitation.
5) What “most specific” formulation combination is explicitly claimed?
Claim 10: soybean oil + polysorbate 80 + PEG 300 (within the broader claim 1 framework, plus the dependent relationships and ranges).
References
- United States Patent No. 10,842,770. (Claim text provided in prompt).
